

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D. C. 20549

---

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act Of 1934

November 10, 2015  
Date of Report (Date of earliest event reported)

---

**ACURA PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in Charter)

---

**State of New York**  
(State of Other Jurisdiction  
of Incorporation)

**1-10113**  
(Commission  
File Number)

**11-0853640**  
(I.R.S. Employer  
Identification Number)

**616 N. North Court, Suite 120**  
**Palatine, Illinois 60067**  
(Address of principal executive offices) (Zip Code)

**(847) 705-7709**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d- 2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e- 4(c))
-

**Item 8.01        Other Events**

On November 10, 2015 we issued a press release announcing receipt of the 2015 North American Opioid Oral Abuse Deterrence Technology Innovation Leadership Award from independent analyst firm Frost & Sullivan. The press release is attached hereto as Exhibit 99.1.

**Item 9.01        Financial Statements and Exhibits**

<u><b>Exhibit Number</b></u>	<u><b>Description</b></u>
------------------------------	---------------------------

99.1	Press Release dated November 10, 2015
------	---------------------------------------

---

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

### **ACURA PHARMACEUTICALS, INC.**

By: /s/ Peter A. Clemens  
Peter A. Clemens  
Senior Vice President & Chief Financial Officer

Date: November 10, 2015

---

**Exhibit Index**

**Exhibit Number**

**Description**

99.1	Press Release dated November 10, 2015
------	---------------------------------------

---



## **Acura Pharmaceuticals Receives 2015 Frost & Sullivan North American Opioid Oral Abuse-Deterrence Technology Innovation Award**

*Limitx™ Technology Recognized as Unique Among Existing Abuse Deterrent Technologies*

Palatine, IL – (November 10, 2015) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating [abuse-deterrent drugs](#), announced that it received the 2015 North American Opioid Oral Abuse Deterrence Technology Innovation Leadership Award from independent analyst firm Frost & Sullivan.

Acura received the Award for its proprietary Limitx™ Technology, which is intended to reduce or limit the rate or extent of opioid release when multiple tablets are ingested.

This Frost & Sullivan Award recognized Acura for its innovative approach to addressing the most prevalent forms of opioid abuse and which offers the potential to become an industry standard. In selecting Acura, Frost & Sullivan industry analysts compared market participants and measured performance through interviews, analysis and secondary research to identify best practices in the industry.

To read the full report, visit [www.acurapharm.com](http://www.acurapharm.com)

### **About Acura Pharmaceuticals**

Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary LIMITX™, AVERSION® and IMPEDE® Technologies. LIMITX contains ingredients that are intended to reduce or limit the rate or extent of opioid release when multiple tablets are ingested. AVERSION contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nasal passages if the product is snorted. IMPEDE is designed to disrupt the processing of pseudoephedrine from tablets into methamphetamine.

### **Forward-Looking Statements**

Certain statements in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forwarding-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking results, performance, or achievements expressed or implied by such forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail in our filings with the Securities and Exchange Commission.

---

**Contact:**  
**for Acura Investor Relations**  
investors@acurapharm.com  
847-705-7709

**Renmark Financial Communications Inc.**  
Robert Thaemlitz: rthaemlitz@renmarkfinancial.com  
Media – D. Elizabeth Culley: dculley@renmarkfinancial.com  
(416) 644-2020 or (514) 939-3989  
www.renmarkfinancial.com

---